Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Medarex, Immuno-Designed cancer deal

The companies partnered to combine MEDX's MDX-010 anti- CTLA-4

Read the full 92 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE